P129 - Expression of Her2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder- preservation chemotherapy
Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): E. Elkhouly, A. Samir, N. Alkady
AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n = 27,385...
AbstractBackgroundThe density of tumor-infiltrating lymphocytes (TIL) is a predictive factor for response to neoadjuvant systemic therapy (NAST) in breast cancer. High TIL density correlates with higher complete pathologic remission (pCR) in triple negative and HER2 positive breast cancer. Additionally, not only TIL density but also subsets of immune cells in tumor stroma seem to play an important role in cancer and immune cell interaction and response to chemotherapy. Our aim is to determine TIL density and expression of CD 20, CD3, CD8, PD-L1, FOXP3 and PGM1 on core biopsy specimen and find a correlation with pCR.Trial d...
ConclusionsThe results of our study could be useful for enhance the role of MTD and identify unmet needs in decision making process in EBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
ConclusionsDevelopment of PD-1 B-cell vaccine was successful, showing no evidence of toxicity or autoimmunity in mice, rabbits and beagle dogs. The combination vaccines could provide improved outcomes in early stage disease sparing patients the toxicity of chemotherapy. A phase 1 clinical trial with the PD-1 vaccine is under planning.Legal entity responsible for the studyThe authors.FundingNIH; Imugene.DisclosureAll authors have declared no conflicts of interest.
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; ERBB2 Gene Amplification; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; PIK3CA Gene Mutation; PTEN Gene Mutation Interventions: Drug: Copanlisib; Biological: Pertuzumab; Biological: Trastuzumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma Metastatic in the Bone; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Paclitaxel; Radiation: Radium Ra 223 Dichloride Sponsor: National Cancer Institute (NCI) Not yet recruiting